NOVEL ANTI-cMET ANTIBODY
AssigneePierre Fabre Medicament
InventorsLiliane GOETSCH, Thierry Wurch, Cedric Bes
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both is a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Claims25
A monoclonal antibody, or a divalent functional fragment or derivative thereof, capable to inhibit the c-Met dimerization, said antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 with respectively the amino acid sequences SEQ ID Nos. 1, 2 and 3;
- and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 with respectively the amino acid sequences SEQ ID Nos. 5, 6 and 7, said antibody being further characterized in that it also comprises a hinge region comprising the amino acid sequence SEQ ID No. 56.
-14. (canceled)
(canceled)
(canceled)
-28. (canceled)
A method for inhibiting the growth or proliferation of a MET amplified or c-Met overexpressing tumor comprising administering an effective dose of an anti-cMET monoclonal antibody, or a cMET-binding fragment thereof, comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 with respectively the amino acid sequences SEQ ID Nos. 1, 2 and 3;
- and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 with respectively the amino acid sequences SEQ ID Nos. 5, 6 and 7, and a hinge region comprising the amino acid sequence SEQ ID No. 56.
-35. (canceled)
Dependencies are inferred from the claim text.